Drug Trial Radar · NCT06447025
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Jan 25, 2024
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Larimar Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and adults with FRDA who have not participated in a prior clinical study of CTI-1601.
Conditions
- Friedreich Ataxia
Interventions
CTI-1601Drug
CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in patients with Friedreich's ataxia
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with treatment-emergent adverse events (TEAEs) by System Organ Class (SOC), Preferred Term (PT) and Maximum SeverityTime frame: Up to 24 months
- Change from baseline in electrocardiogram (ECG) parameters including, but not limited to, HR, RR interval, PR interval, QRS duration, QT interval, and QTcF intervalTime frame: Up to 24 months
- Change from baseline in left ventricular ejection fraction (LVEF)Time frame: Up to 24 months
- Change from baseline in left ventricular end-diastolic volume (LVEDV)Time frame: Up to 24 months
- Number of subjects with any suicidal ideation or behavior (Categories 1-10) of the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 24 months
- Change from baseline at each collection timepoint in tissue frataxin concentrations normalized to total protein observed in buccal cells collected from cheek swabs and skin cells collected from skin punch biopsiesTime frame: Up to 24 months
- Change from baseline in motor function as assessed by 9-hole peg test (9-HPT)Time frame: Up to 24 months
- Change from baseline in motor function as assessed by the timed 25-foot walk test (T25-FW)Time frame: Up to 24 months
- Change from baseline in neurologic function as assessed by the modified Friedreich's Ataxia Rating Scale (mFARS) total scoreTime frame: Up to 24 months
- Change from baseline in neurologic function as assessed by the upright stability subscale examination of the mFARSTime frame: Through study completion, up to 24 months
- Change in activities of daily living (ADLs) as assessed by the Friedreich's Ataxia Rating Scale Activities of Daily Living (FARS_ADL)Time frame: Up to 24 months
- Change from baseline in total fatigue score and all the subscale scores as assessed by the Fatigue Impact Scale (MFIS)Time frame: Up to 24 months
- Change from baseline in the assessment of disease as assessed by the Functional Staging for AtaxiaTime frame: Up to 24 months
- Overall impression of change as assessed by the patient using the Patient Global Impression of Change (PGI-C) ScaleTime frame: Up to 24 months
- Overall impression of change assessed by a clinician using the Clinical Global Impression of Change (CGI-C)Time frame: Up to 24 months
- Area under the concentration-time curve for the dosing interval (AUC0-tau)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
- Area under the concentration-time curve from time 0 to the time of last quantifiable concentration (AUC0-t)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
- Mean maximum observed concentration (Cmax)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
- Mean time of maximum observed concentration (Tmax)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
- Concentration reached immediately before the next dose is administered (Ctrough)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California · Active not recruiting
University of California, San Franciso Medical Center
San Francisco, California · Recruiting
Fixel Institute for Neurological Disease, University of Florida Health
Gainesville, Florida · Active not recruiting
Morsani Center for Advanced Health Care, University of South Florida Health
Tampa, Florida · Recruiting
University of Iowa Hospitals & Clinics
Iowa City, Iowa · Recruiting
Uncommon Cures
Chevy Chase, Maryland · Recruiting
Clinilabs Drug Development, Corp.
Eatontown, New Jersey · Recruiting
Ohio State University Wexner Medical Center
Columbus, Ohio · Active not recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
ICON
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.